

Daniel B Costa

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2724878/daniel-b-costa-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

17,397
citations

46
h-index

131
g-index

186
ext. papers

19,989
ext. citations

6.3
avg, IF

6.26
L-index

#	Paper	IF	Citations
169	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
168	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4247-53	2.2	1462
167	Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1963-71	59.2	1267
166	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology, The</i> , 2012 , 13, 1011-9	21.7	983
165	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016 , 7, 10501	17.4	846
164	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology, The</i> , 2011 , 12, 1004-12	21.7	732
163	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1881-8	2.2	454
162	CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. <i>Journal of Clinical Oncology</i> , 2011 , 29, e443-5	2.2	450
161	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. <i>Lancet Oncology, The</i> , 2012 , 13, e23-31	21.7	401
160	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. <i>PLoS Medicine</i> , 2007 , 4, 1669-79; discussion 1680	11.6	376
159	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. <i>Nature</i> , 2012 , 483, 613-7	50.4	361
158	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015 , 6, 6377	17.4	358
157	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3307-15	2.2	343
156	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018 , 4, 1527-1534	13.4	342
155	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. <i>Clinical Lung Cancer</i> , 2009 , 10, 281-9	4.9	330
154	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. <i>Science Translational Medicine</i> , 2013 , 5, 216ra177	17.5	313
153	Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. <i>Lung Cancer</i> , 2015 , 88, 108-11	5.9	243

152	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2858-65 ^{2.2}	171
151	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. <i>Clinical Cancer Research</i> , 2010 , 16, 5873-82	168
150	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1670-4	166
149	Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. <i>Nature Genetics</i> , 2006 , 38, 1269-77	146
148	The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. <i>Clinical Cancer Research</i> , 2012 , 18, 4406-14	144
147	Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. <i>Lung Cancer</i> , 2007 , 58, 95-103	140
146	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. <i>Clinical Cancer Research</i> , 2008 , 14, 7060-7	135
145	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1086-90	124
144	Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 45-51	114
143	Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. <i>Lung Cancer</i> , 2017 , 106, 17-21	111
142	Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1182-4; author reply 1184-6	110
141	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 38789-803	104
140	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 84, 39-44	103
139	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. <i>Therapeutic Advances in Respiratory Disease</i> , 2016 , 10, 113-29 ^{4.9}	97
138	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 50% Expression in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 878-883	94
137	A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2611-20	93
136	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 6010-6020	84
135	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 97-104	83

134	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. <i>Annals of Oncology</i> , 2013 , 24, 59-66	10.3	82
133	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. <i>Therapeutic Advances in Medical Oncology</i> , 2011 , 3, 113-25	5.4	77
132	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. <i>Lung Cancer</i> , 2014 , 83, 37-43	5.9	68
131	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1048-53	8.9	68
130	Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1438-1444	8.9	64
129	Management and future directions in non-small cell lung cancer with known activating mutations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e353-65	7.1	62
128	Eatenin contributes to lung tumor development induced by EGFR mutations. <i>Cancer Research</i> , 2014 , 74, 5891-902	10.1	60
127	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. <i>Lung Cancer</i> , 2015 , 90, 369-74	5.9	59
126	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1037-1042	8.9	58
125	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021 , 11, 1688-1699	24.4	57
124	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019 , 133, 96-102	5.9	53
123	The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 383-90	3.5	46
122	Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1288-1298	8.9	44
121	Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9007-9007	2.2	43
120	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. <i>Journal of the American Society of Cytopathology</i> , 2018 , 7, 133-141	2.4	42
119	Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5963-5976	12.9	42
118	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. <i>Lung Cancer</i> , 2013 , 82, 31-7	5.9	42
117	EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. <i>Clinical Lung Cancer</i> , 2016 , 17, 483-492	4.9	41

116	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. <i>Blood</i> , 2010 , 115, 2901-9	2.2	41
115	Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. <i>Translational Lung Cancer Research</i> , 2015 , 4, 809-15	4.4	39
114	Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. <i>Translational Lung Cancer Research</i> , 2016 , 5, 331-7	4.4	39
113	Tumor biomarker testing in non-small-cell lung cancer: A decade of change. <i>Lung Cancer</i> , 2018 , 116, 90-95	5.9	38
112	Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1434-7	8.9	37
111	Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. <i>Annals of Oncology</i> , 2018 , 29, 2092-2097	10.3	36
110	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1995-2002	8.9	34
109	miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. <i>Nature Metabolism</i> , 2019 , 1, 460-474	14.6	32
108	Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. <i>Lung Cancer</i> , 2013 , 79, 193-7	5.9	32
107	Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. <i>Lung Cancer</i> , 2008 , 61, 152-62	5.9	32
106	Targeting rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. <i>Translational Cancer Research</i> , 2018 , 7, S779-S786	0.3	32
105	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018 , 24, 6548-6555	12.9	31
104	Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. <i>Diabetes Care</i> , 2006 , 29, 1711	14.6	30
103	MA04.02 Neratinib + Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S358-S359	8.9	29
102	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1183-1209	8.9	29
101	Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. <i>Lung Cancer</i> , 2012 , 77, 31-7	5.9	29
100	Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth. <i>Oncotarget</i> , 2016 , 7, 23919-32	3.3	28
99	Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 918-23	8.9	25

98	TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant Mutations. <i>Molecular Cancer Research</i> , 2019 , 17, 2233-2243	6.6	24
97	Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. <i>Clinical Lung Cancer</i> , 2017 , 18, e349-e356	4.9	23
96	Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. <i>Cancer Treatment Communications</i> , 2015 , 4, 174-181		22
95	De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. <i>Lung Cancer</i> , 2015 , 88, 70-3	5.9	21
94	The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. <i>Clinical Lung Cancer</i> , 2015 , 16, 334-339.e1	4.9	21
93	EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e19-20	8.9	21
92	Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e23-4	8.9	20
91	Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules \geq 0 mm on CT: Radiology-Pathology Correlation. <i>Academic Radiology</i> , 2017 , 24, 851-859	4.3	19
90	Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients. <i>Journal of Infection</i> , 2005 , 50, 130-7	18.9	19
89	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. <i>Lung Cancer</i> , 2020 , 145, 181-185	5.9	18
88	ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1439-40	8.9	18
87	Molecular testing in lung cancer: the time is now. <i>Current Oncology Reports</i> , 2010 , 12, 335-48	6.3	18
86	Pneumococemia as the presenting feature of multiple myeloma. <i>American Journal of Hematology</i> , 2004 , 77, 277-81	7.1	18
85	First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9015-9015	2.2	18
84	Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. <i>Lung Cancer</i> , 2007 , 56, 97-103	5.9	17
83	Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e81-2	8.9	16
82	Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. <i>Journal of the National Medical Association</i> , 2006 , 98, 1183-7	2.3	16
81	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. <i>Translational Lung Cancer Research</i> , 2015 , 4, 392-403	4.4	16

80	PI-RADS Version 2.1: A Critical Review, From the Special Series on Radiology Reporting and Data Systems. <i>American Journal of Roentgenology</i> , 2021 , 216, 20-32	5.4	16
79	Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. <i>JAMA Network Open</i> , 2021 , 4, e2037120	10.4	16
78	C/EBP alpha mutations in lung cancer. <i>Lung Cancer</i> , 2006 , 53, 253-4	5.9	15
77	A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred. <i>Blood</i> , 2005 , 106, 4367-9	2.2	15
76	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. <i>Lung Cancer</i> , 2016 , 99, 17-22	5.9	13
75	Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population. <i>Jornal Brasileiro De Pneumologia</i> , 2009 , 35, 767-72	1.1	12
74	Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. <i>JAMA Oncology</i> , 2016 , 2, 1240-2	13.4	12
73	Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? 2020 , 8,		11
72	Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 248-53	8.9	11
71	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e175-e177	8.9	10
70	Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016 , 24, 187-204	1.6	10
69	"Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines. <i>Academic Radiology</i> , 2017 , 24, 1422-1427	4.3	10
68	Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 623-5	8.9	10
67	A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2006 , 76, 432-5, 453	3.8	10
66	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8015-8015	2.2	10
65	P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1302-S1303	8.9	9
64	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. <i>Clinical Lung Cancer</i> , 2015 , 16, e105-9	4.9	9
63	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2020 , 1,	1.4	9

62	Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. <i>Clinical Lung Cancer</i> , 2018 , 19, e589-e590	4.9	9
61	Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9507-9507	2.2	9
60	Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?. <i>Precision Cancer Medicine</i> , 2020 , 3,	1	8
59	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. <i>Cancer Treatment and Research Communications</i> , 2018 , 15, 17-20	2	7
58	ALK inhibitors: plateauing systemic and intracranial activity?. <i>Lancet Oncology, The</i> , 2016 , 17, 404-406	21.7	6
57	Serum concentrations of Erlotinib at a dose of 25 mg daily. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1311-28.9		6
56	Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by -D1228 and -Y1230 Mutations in -Mutated -Amplified Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100071	1.4	6
55	Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations. <i>JTO Clinical and Research Reports</i> , 2021 , 2,	1.4	6
54	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. <i>Oncologist</i> , 2021 , 26, 281-287	5.7	6
53	Safety of cupping during bevacizumab therapy. <i>Journal of Alternative and Complementary Medicine</i> , 2013 , 19, 729-31	2.4	5
52	Three-year survival in metastatic non-small cell lung cancer treated with gefitinib. <i>Lung Cancer</i> , 2006 , 53, 123-4	5.9	5
51	Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. <i>Frontiers in Oncology</i> , 2020 , 10, 1193	5.3	5
50	The rapidly evolving landscape of biomarker testing in non-small cell lung cancer. <i>Cancer Cytopathology</i> , 2021 , 129, 179-181	3.9	5
49	Ascending role of next-generation ALK inhibitors. <i>Lancet Oncology, The</i> , 2017 , 18, 837-839	21.7	4
48	Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e1-e3	8.9	4
47	More than just an oncogene translocation and a kinase inhibitor: Kevin's story. <i>Journal of Clinical Oncology</i> , 2012 , 30, 110-2	2.2	4
46	Abstract 23: Sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR 2012 ,		4
45	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100074	1.4	4

44	Rapidly fatal advanced -mutated lung cancers and the need for rapid tumor genotyping in clinical practice. <i>Cancer Treatment and Research Communications</i> , 2016 , 9, 41-43	2	4
43	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e379-e389	4.9	4
42	P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1072-S1073	8.9	3
41	Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline. <i>JAAD Case Reports</i> , 2015 , 1, 289-91	1.4	3
40	Endoluminal contrast for abdomen and pelvis magnetic resonance imaging. <i>Abdominal Radiology</i> , 2016 , 41, 1378-98	3	3
39	EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. <i>Targeted Oncology</i> , 2014 , 9, 389-94	5	3
38	De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. <i>Lung Cancer</i> , 2017 , 114, 108-110	5.9	3
37	Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?. <i>Cell Cycle</i> , 2017 , 16, 19-20.7	4.7	3
36	Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. <i>Journal of Oncology Practice</i> , 2012 , 8, 57-62	3.1	3
35	To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress. <i>Lung Cancer</i> , 2007 , 57, 251-2	5.9	3
34	Erlotinib-associated alopecia in a lung cancer patient. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 1136-8	8.9	3
33	Recurrent infections in multiple myeloma. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 567-8; author reply 568	6.4	3
32	Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature. <i>Endocrine Practice</i> , 2004 , 10, 417-23	3.2	3
31	Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e35-e36	8.9	2
30	Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations. <i>Journal of Clinical Oncology</i> , 2008 , 26, 686	2.2	2
29	A Position +5 Intronic Mutation in the β -Spectrin Gene Is Associated with Marked Deficiency of β -Spectrin Production in the First Reported Cases of Hereditary Pyropoikilocytosis.. <i>Blood</i> , 2004 , 104, 576-576	2.2	2
28	Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8507-8507	2.2	2
27	CCAAT/enhancer binding protein β s dispensable for development of lung adenocarcinoma. <i>PLoS ONE</i> , 2015 , 10, e0120647	3.7	2

26	Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer. <i>Translational Lung Cancer Research</i> , 2014 , 3, 373-5	4.4	2
25	Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis. <i>Clinical Lung Cancer</i> , 2020 , 21, e6-e9	4.9	2
24	Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib. <i>JACC: CardioOncology</i> , 2020 , 2, 119-122	3.8	2
23	Time to SARS-CoV-2 clearance among patients with cancer and COVID-19. <i>Cancer Medicine</i> , 2021 , 10, 1545-1549	4.8	2
22	Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT. <i>Journal of Thoracic Disease</i> , 2017 , 9, E1148-E1150	2.6	1
21	EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20593-e20593	2.2	1
20	Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9533-9533	2.2	1
19	Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer		1
18	Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. <i>Translational Cancer Research</i> , 2017 , 6, S151-S157	0.3	1
17	Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III -Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021 , 5, 325-332	3.6	1
16	Time to COVID-19 RT-PCR clearance among patients with cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 49-49	2.2	0
15	Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 1769-1770	59.2	0
14	Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naïve Programmed Death Ligand 1-Positive Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e34-e36	8.9	
13	Updated Correlation of 22C3-PD-L1 B0% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e81-e83	8.9	
12	Thymic carcinoma with brain metastases: A rare presentation of a rare malignancy. <i>Cancer Treatment Communications</i> , 2016 , 7, 21-22		
11	KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 220-2	8.9	
10	Gefitinib plus docetaxel in non-small-cell lung cancer. <i>Lancet, The</i> , 2009 , 373, 541; author reply 542	4.0	
9	5-Azacytidine treatment of the patient with ATMDS. <i>European Journal of Haematology</i> , 2006 , 76, 453-453.8		

8	Hyperglycemia and biliary tract adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 484-5	4
7	Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7740-2	2.2
6	A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 3175-3175	2.2
5	PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20617-e20617	2.2
4	Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21579-e21579	2.2
3	Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for -Amplified Tumors With -D1228X or -Y1230X Mutations. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100133	1.4
2	Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence. <i>Clinical Lung Cancer</i> , 2016 , 17, e169-e172	4.9
1	AuthorsLResponse. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e237	8.9